There is no female version of Viagra itself, but two FDA-approved medications treat low sexual desire in women. They work completely differently from Viagra, targeting brain chemistry rather than blood flow. Understanding what these drugs actually do, how well they work, and who they’re designed for can help you figure out whether they’re worth exploring.
Why Viagra Itself Doesn’t Work the Same Way for Women
Viagra (sildenafil) solves a straightforward plumbing problem: it relaxes blood vessels in the penis so more blood flows in during arousal. It blocks an enzyme called PDE5, which lets blood vessels stay dilated longer. That mechanism works well for erections, but female sexual desire and arousal involve a much more complex interplay of brain signals, hormones, and physical response.
Researchers have tested sildenafil in women. Some small trials found it could improve physical arousal and reduce the time to orgasm in specific groups, including postmenopausal women on hormone therapy and women whose antidepressants had dampened their sexual function. But these results were inconsistent and narrow. Increasing blood flow to the genitals doesn’t reliably increase desire, which is the core complaint most women with sexual dysfunction report. The problem, for most women, starts in the brain rather than in the blood vessels.
The Two FDA-Approved Options
Both medications approved for women target a condition called hypoactive sexual desire disorder, or HSDD. This isn’t just a temporary dip in libido from stress or a rough patch in a relationship. The diagnostic criteria require persistently low or absent sexual desire that causes significant personal distress. Both drugs are approved only for premenopausal women.
Flibanserin (Addyi)
Flibanserin is a daily pill taken at bedtime. It works on serotonin, dopamine, and norepinephrine, three brain chemicals that influence mood, motivation, and sexual interest. Specifically, it activates one type of serotonin receptor while blocking another, and this combination gradually boosts dopamine and norepinephrine levels in the prefrontal cortex. Dopamine plays a role in boosting desire, while norepinephrine helps stimulate arousal. The net effect is a slow, cumulative shift in brain chemistry that can increase sexual interest over weeks of daily use.
Because it’s a daily medication that reshapes neurotransmitter balance over time, flibanserin isn’t something you take before sex. You take it every night at bedtime (which also helps manage its most common side effects: dizziness, sleepiness, and nausea). Most women need to take it for at least four to eight weeks before noticing a meaningful change.
The biggest practical concern with flibanserin is alcohol. Combining the two, even close together in time, raises the risk of dangerously low blood pressure and fainting. The current FDA guidance is specific: wait at least two hours after one or two drinks before taking your dose at bedtime. If you’ve had three or more drinks that evening, skip the dose entirely. After taking flibanserin, avoid alcohol until the following day.
Bremelanotide (Vyleesi)
Bremelanotide takes a different approach. It activates melanocortin receptors in the brain, particularly MC4R, a receptor linked to appetite and sexual desire. Instead of a daily pill, it’s a self-administered injection (using a pre-filled autoinjector, similar to an EpiPen) that you give yourself in the abdomen or thigh at least 45 minutes before anticipated sexual activity.
This on-demand format appeals to women who don’t want to take a daily medication or deal with the alcohol restrictions that come with flibanserin. However, bremelanotide has its own limits. You shouldn’t use it more than once in a 24-hour period, and the recommended maximum is eight doses per month. The most common side effect is nausea, which tends to be worst with the first few injections and often improves over time. Some women also experience flushing, headache, or a temporary reaction at the injection site.
How They Compare to Viagra’s Effectiveness
Viagra produces a clear, measurable physical result in a high percentage of men who take it. The female options are subtler. In clinical trials, both flibanserin and bremelanotide showed statistically significant improvements in sexual desire scores and reductions in distress related to low desire compared to placebo. But the improvements were modest on average, and not every woman responds.
This doesn’t mean they’re useless. Sexual desire is harder to quantify than an erection, and even moderate improvements in desire and reduced distress can meaningfully change someone’s quality of life and relationship satisfaction. The clinical trials measured averages across large groups, which tends to flatten the picture. Some women see significant benefit while others notice little change. Most prescribers recommend trying the medication for a set period and evaluating whether it’s making enough of a difference to continue.
Why the Biology Is More Complicated
The reason there’s no simple “pink pill” equivalent of Viagra comes down to what drives sexual dysfunction differently in men and women. Male erectile dysfunction is often primarily vascular: the signals for arousal are working, but blood flow isn’t keeping up. A drug that enhances blood flow can fix the bottleneck without touching the brain.
Low desire in women, by contrast, typically involves the central nervous system. The balance of excitatory and inhibitory signals in the brain determines whether desire surfaces or gets suppressed. Serotonin generally acts as a brake on sexual desire (which is why antidepressants that raise serotonin often kill libido), while dopamine and norepinephrine act as accelerators. Flibanserin essentially tries to ease off the brake while pressing the accelerator. Bremelanotide takes a separate route through the melanocortin system, which sits at a different crossroads of appetite, reward, and desire.
Neither approach is as clean or direct as blocking a single enzyme in a blood vessel. That’s not a failure of the drugs so much as a reflection of how desire works. It’s generated across multiple brain systems, shaped by hormones, stress, relationship dynamics, sleep, and more. A pill can nudge the neurochemistry, but it’s working on a system with many more moving parts.
What to Expect Practically
If you’re considering one of these medications, here’s what the experience typically looks like. With flibanserin, you’ll take a pill every night at bedtime and need to plan around alcohol. You may feel drowsy or mildly nauseated in the first few weeks. Improvement, if it comes, builds gradually over a month or two. If you don’t notice a difference after eight weeks, the medication probably isn’t working for you.
With bremelanotide, you’ll use a pre-filled autoinjector when you want it, giving yourself a shot in the stomach or thigh about 45 minutes beforehand. Nausea is common, especially the first few times, and can last a couple of hours. Some women find it manageable; others find it disruptive enough to stop. The on-demand format means you only deal with side effects on the days you use it, which some women prefer.
Neither medication is designed for women whose low desire is explained by a medical condition, a medication side effect (like from antidepressants), relationship problems, or other identifiable causes. They’re meant for women who have persistently low desire with no clear external explanation, and who are genuinely distressed by it. That distinction matters, because if a fixable cause exists, addressing it directly will almost always work better than adding a new medication on top.